Article (Scientific journals)
Growth hormone (GH) secretion in patients with childhood-onset GH deficiency: Retesting after one year of therapy and at final height
Thomas, Muriel; Massa, Guy; Maes, Maes et al.
2003In Hormone Research, 59 (1), p. 7-15
Peer Reviewed verified by ORBi
 

Files


Full Text
ThomasM_retesting (Horm Res 2003) postprint auteur.doc
Author postprint (335.87 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
idiopathic growth hormone deficiency; growth hormone treatment; retesting
Abstract :
[en] Background. Recent studies have shown that many patients treated with growth hormone (GH) during childhood because of idiopathic GH deficiency (GHD) are no longer GH deficient when retested after cessation of GH therapy when final height is achieved. These patients are labelled as transient GHD. We hypothesized that normalization of GH secretion in transient GHD could occur earlier during the course of GH treatment, which could allow earlier cessation of GH treatment. Methods: In a retrospective study, GH secretion was re-evaluated after cessation of GH treatment at final height in 43 patients diagnosed during childhood as idiopathic GHD 10 with multiple pituitary hormonal deficiencies (MPHD) and 33 with isolated GHD ([sGHD]). In a prospective study, GH secretion was re-assessed after interruption of GH treatment given for 1 year in 18 children with idiopathic GHD (2 MPHD, 16 IsGHD). GH secretion was evaluated by glucagon or insulin stimulation tests. Results: In the retrospective study, all the 10 patients with MPHD and 64% of the 33 patients with IsGHD were still deficient at re-evaluation using the paediatric criteria to define GHD (GH peak < 10 ng/ml at provocative test). The proportion of persisting deficiency was greater in patients with complete IsGHD (86%, 12/14 patients) than in patients with partial IsGHD (47%, 9/19 patients). With the criteria proposed in adulthood (GH peak <3 ng/ml), all the 10 patients with MPHD were still considered to be deficient. In contrast, only 15% (5/33 patients) with IsGHD had a maximal GH value < 3 ng/ml (36% of the 14 patients with complete IsGHD and none of the 19 patients with partial IsGHD). In the prospective study, after interruption of GH therapy given for 1 year, the 2 patients with MPHD were still GHD at re-evaluation and they resumed GH treatment. Among the 16 patients with IsGHD, 13 (81%) were still deficient (peak response < 10 ng/ml) after 1 year. Two of the 3 patients in whom GHD was not confirmed at retesting after 1 year GH showed again a deficient response at second retesting. Conclusions: Although many patients diagnosed with IsGHD during childhood have a normalized GH secretory capacity when retested during adulthood, early retesting after interruption of GH treatment given for 1 year during childhood does not enable to determine if GH therapy has to be discontinued before cessation of growth. Copyright (C) 2003 S. Karger AG, Basel.
Research center :
Giga-Neurosciences - ULiège
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Thomas, Muriel
Massa, Guy
Maes, Maes
Beckers, Dominique
Craen, Margarita
Francois, Inge
Heinrichs, Claudine
Bourguignon, Jean-Pierre ;  Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie
Language :
English
Title :
Growth hormone (GH) secretion in patients with childhood-onset GH deficiency: Retesting after one year of therapy and at final height
Publication date :
2003
Journal title :
Hormone Research
ISSN :
0301-0163
eISSN :
1423-0046
Publisher :
Karger, Basel, Switzerland
Volume :
59
Issue :
1
Pages :
7-15
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
BSGPE - Belgian Study Group for Pediatric Endocrinology [BE]
Available on ORBi :
since 02 September 2011

Statistics


Number of views
235 (3 by ULiège)
Number of downloads
147 (1 by ULiège)

Scopus citations®
 
29
Scopus citations®
without self-citations
28
OpenCitations
 
13

Bibliography


Similar publications



Contact ORBi